Glancy Binkow & Goldberg Announces a November 18, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against Edwards

Glancy Binkow & Goldberg Announces a November 18, 2013 Lead Plaintiff Deadline
in the Class Action Lawsuit Against Edwards Lifesciences Corporation -- EW

LOS ANGELES, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Glancy Binkow & Goldberg LLP,
announces that all purchasers of Edwards Lifesciences Corporation ("Edwards
Lifesciences" or the "Company") (NYSE:EW) between April 25, 2012 and April 23,
2013, inclusive (the "Class Period'), have until November 18, 2013 to file a
motion to be appointed as lead plaintiff in the shareholder lawsuit filed in
the United States District Court for the Central District of California.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW &
GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888)
773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER OR IF YOU
PURCHASED SHARES BEFORE THE CLASS PERIOD. IF YOU INQUIRE BY EMAIL PLEASE
INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

Edwards Lifesciences is a medical device maker that designs and markets, among
other things, artificial heart valves for implantation in patients with
advanced cardiovascular disease. The Company's SAPIEN line of transcatheter
heart valves may be implanted using a minimally invasive procedure.

The Complaint alleges that the Company issued false and/or misleading
statements and failed to disclose material facts related to the prospects,
projected sales and adoption of the Company's Edwards SAPIEN transcatheter
aortic heart valve, including the related transfemoral and transapical
delivery methods ("SAPIEN"), and related projections of financial performance
for the Company's operations. Specifically, the Complaint alleges that the
defendants knew but concealed from Edwards Lifesciences' shareholders during
the Class Period that:

  *Adoption of SAPIEN was weaker than the Company claimed, due to concerns
    among physicians over the risks and complexity of the procedure for
    implanting the valve.
  *Edwards Lifesciences' outlook for sales and earnings per share was
    significantly weaker than the optimistic guidance defendants offered to
    investors.
  *Defendants lacked a reasonable basis for the statements made concerning
    the Company's operations, forecasts and outlook.

If you are a member of the above-described Class you may move the Court no
later than November 18, 2013 to serve as lead plaintiff; however, you must
meet certain legal requirements. To be a member of the Class you need not take
any action at this time; you may retain counsel of your choice or take no
action and remain an absent member of the Class.

To learn more about this action or if you have any questions concerning this
Notice or your rights or interests with respect to these matters, please
contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925
Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at
(888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg
LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212)
682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

CONTACT: Glancy Binkow & Goldberg LLP, Los Angeles, CA
         Michael Goldberg
         (888) 773-9224
         Glancy Binkow & Goldberg LLP, New York, NY
         Gregory Linkh
         (212) 682-5340
         shareholders@glancylaw.com
         www.glancylaw.com

Company Logo